CN104736152B - 包含3‑甲酰基利福霉素sv和3‑甲酰基利福霉素s的3‑(4‑肉桂基‑1‑哌嗪基)氨基衍生物的药物制剂以及它们的制备方法 - Google Patents

包含3‑甲酰基利福霉素sv和3‑甲酰基利福霉素s的3‑(4‑肉桂基‑1‑哌嗪基)氨基衍生物的药物制剂以及它们的制备方法 Download PDF

Info

Publication number
CN104736152B
CN104736152B CN201380053241.6A CN201380053241A CN104736152B CN 104736152 B CN104736152 B CN 104736152B CN 201380053241 A CN201380053241 A CN 201380053241A CN 104736152 B CN104736152 B CN 104736152B
Authority
CN
China
Prior art keywords
formylrifamycin
cinnamyl
piperazinyl
preparation
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380053241.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN104736152A (zh
Inventor
R·G·康斯坦丁诺瓦
基里尔·阿瑟诺夫·尼诺夫
卫理士卡·里列瓦·阿波斯托洛娃-迪莫瓦
伊夫提米亚·伊万诺瓦·斯戴凡诺瓦
罗森·克鲁莫夫·科伊特切夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Base Lille A Senuofu Nino Husband
Di Teqiefu Seeks Advice From Co Ltd
In Ibo Mil Bo Zhidanuofufudulu Husband
Luo Sen Crewe is husband Coe Te Qiefu not
Single Joint-Stock Co Of A Dipamu
Wei Lishikaliliewaa Persian Tuo Luowa-Di Mowa
Yi Futi Meter Ya Yiwan Nova Si Daifan Nova
Original Assignee
DITCHEV CONSULTING OOD
FUDULOV BOZHIDAR LYUBENOV
FUDULOV LYIBOMIR BOZHIDAROV
ADIPHARM EAD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DITCHEV CONSULTING OOD, FUDULOV BOZHIDAR LYUBENOV, FUDULOV LYIBOMIR BOZHIDAROV, ADIPHARM EAD filed Critical DITCHEV CONSULTING OOD
Priority to CN201711346387.6A priority Critical patent/CN107840854A/zh
Publication of CN104736152A publication Critical patent/CN104736152A/zh
Application granted granted Critical
Publication of CN104736152B publication Critical patent/CN104736152B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Inorganic Chemistry (AREA)
CN201380053241.6A 2012-08-13 2013-08-09 包含3‑甲酰基利福霉素sv和3‑甲酰基利福霉素s的3‑(4‑肉桂基‑1‑哌嗪基)氨基衍生物的药物制剂以及它们的制备方法 Active CN104736152B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201711346387.6A CN107840854A (zh) 2012-08-13 2013-08-09 3‑甲酰基利福霉素sv的3‑(4‑肉桂基‑1‑哌嗪基)氨基衍生物的用途和制备方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
BG11128812 2012-08-13
BG111288 2012-08-13
PCT/BG2013/000041 WO2014026254A1 (en) 2012-08-13 2013-08-09 Pharmaceutical formulations containing 3-(4-cinnamyl-l-piperazinyl) amino derivatives of 3-formylrifamycin sv and 3-formylrifamycin s and a process of their preparation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201711346387.6A Division CN107840854A (zh) 2012-08-13 2013-08-09 3‑甲酰基利福霉素sv的3‑(4‑肉桂基‑1‑哌嗪基)氨基衍生物的用途和制备方法

Publications (2)

Publication Number Publication Date
CN104736152A CN104736152A (zh) 2015-06-24
CN104736152B true CN104736152B (zh) 2018-01-23

Family

ID=50101135

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380053241.6A Active CN104736152B (zh) 2012-08-13 2013-08-09 包含3‑甲酰基利福霉素sv和3‑甲酰基利福霉素s的3‑(4‑肉桂基‑1‑哌嗪基)氨基衍生物的药物制剂以及它们的制备方法
CN201711346387.6A Pending CN107840854A (zh) 2012-08-13 2013-08-09 3‑甲酰基利福霉素sv的3‑(4‑肉桂基‑1‑哌嗪基)氨基衍生物的用途和制备方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201711346387.6A Pending CN107840854A (zh) 2012-08-13 2013-08-09 3‑甲酰基利福霉素sv的3‑(4‑肉桂基‑1‑哌嗪基)氨基衍生物的用途和制备方法

Country Status (18)

Country Link
US (2) US9682997B2 (https=)
EP (1) EP2882435B8 (https=)
JP (2) JP6400580B2 (https=)
KR (1) KR102210848B1 (https=)
CN (2) CN104736152B (https=)
BR (1) BR112015002945B1 (https=)
CA (1) CA2881958C (https=)
EA (1) EA029363B1 (https=)
ES (1) ES2876004T3 (https=)
HK (1) HK1248691A1 (https=)
HU (1) HUE054955T2 (https=)
IN (1) IN2015DN02009A (https=)
MX (1) MX380259B (https=)
PL (1) PL2882435T3 (https=)
PT (1) PT2882435T (https=)
UA (1) UA120030C2 (https=)
WO (1) WO2014026254A1 (https=)
ZA (1) ZA201501268B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX386622B (es) * 2017-06-26 2025-03-19 Biofer Spa Derivados de pirido-imidazo rifamicina como agente antibacteriano
TWI731295B (zh) * 2019-01-24 2021-06-21 宏碁股份有限公司 顯示裝置以及控制顯示裝置的方法
CN119243181B (zh) * 2024-10-14 2025-10-10 河北欣港药业有限公司 一种微尺度下由利福霉素sv连续流电化学合成利福霉素s的方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4918066A (en) * 1985-10-18 1990-04-17 Ciba-Geigy Corporation Substituted 4-benzylpiperazinyl compounds
US5095108A (en) * 1990-08-28 1992-03-10 Technologichen Kombinat Za Promishlena Microbiologia Non-solvated crystalline form "A" of 3-(4-cynnamyl-1-piperazinyl)iminomethylrifamycine SV and a method of its production
US6476036B1 (en) * 1998-11-04 2002-11-05 Roumiana Gueorguieva Konstantinova Sodium salt of 3-(4-cinnamyl-1-piperazinyl)-imino-methyl rifamycin SV
CN101065385A (zh) * 2004-07-22 2007-10-31 坎布里制药公司 治疗微生物感染的利福霉素衍生物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1478563A (en) 1975-03-05 1977-07-06 Lepetit Spa Rifamycin derivatives
GR64108B (en) 1977-04-15 1980-01-24 Dso Pharmachim Method for the preparation of azomethine-derivatives of rifamycin s.v
US4179439A (en) * 1977-07-01 1979-12-18 Intreprinderea De Antibiotice Iasi Rifamycins and method for their preparation
US4193020A (en) 1978-05-22 1980-03-11 Sperry Rand Corporation Phase lock control system with trajectory correction
JPS5738742A (en) * 1980-08-21 1982-03-03 Kawasaki Kasei Chem Ltd Preparation of 1,4-dihydroanthraquinone
JPS5695190A (en) * 1980-09-17 1981-08-01 Intorepurinderea De Anteibiote Manufacture of rifamycin derivative
IT1201963B (it) * 1983-03-24 1989-02-02 Prodotti Antibiotici Spa Derivati delle rifamicine e procedimento per la loro preparazione
JPS6143132A (ja) * 1984-08-06 1986-03-01 Takeda Chem Ind Ltd キノン誘導体，その製造法およびそれを含んでなる医薬組成物
IT1202424B (it) * 1987-01-26 1989-02-09 Prodotti Antibiotici Spa Sali di un derivato rifamicinico
EP0284552A1 (de) * 1987-03-06 1988-09-28 Ciba-Geigy Ag 4-Benzyl-piperazinyl-Hydrazone
BG48618A1 (en) 1988-02-23 1991-04-15 Nauchen Inst Promishlena Mikro Method for preparing riphampycin
JPH02215716A (ja) * 1989-02-08 1990-08-28 Farmitalia Carlo Erba Spa ３―（ｎ―ピペリジノメチル―アジノ）メチルリファマイシンｓを活性成分として含有する薬剤組成物
DE10015814A1 (de) * 2000-03-30 2001-10-11 Max Planck Gesellschaft Arzneimittel zur Stimulierung der Leukopoese, zur Behandlung von Tumor- und Protozoenerkrankungen und Verfahren zu seiner Herstellung
DE10038101A1 (de) * 2000-08-04 2002-02-14 Degussa Verfahren zur Herstellung von 2-(4-Methyl-3-pentenyl)-anthrachinon
UA80393C2 (uk) * 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
GB0505909D0 (en) * 2005-03-23 2005-04-27 Univ Leeds Formulations

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4918066A (en) * 1985-10-18 1990-04-17 Ciba-Geigy Corporation Substituted 4-benzylpiperazinyl compounds
US5095108A (en) * 1990-08-28 1992-03-10 Technologichen Kombinat Za Promishlena Microbiologia Non-solvated crystalline form "A" of 3-(4-cynnamyl-1-piperazinyl)iminomethylrifamycine SV and a method of its production
US6476036B1 (en) * 1998-11-04 2002-11-05 Roumiana Gueorguieva Konstantinova Sodium salt of 3-(4-cinnamyl-1-piperazinyl)-imino-methyl rifamycin SV
CN101065385A (zh) * 2004-07-22 2007-10-31 坎布里制药公司 治疗微生物感染的利福霉素衍生物

Also Published As

Publication number Publication date
US9981985B2 (en) 2018-05-29
CA2881958C (en) 2019-08-27
MX2015001963A (es) 2015-06-04
BR112015002945B1 (pt) 2021-08-31
BR112015002945A8 (pt) 2018-01-16
US20170283433A1 (en) 2017-10-05
EP2882435A4 (en) 2017-05-03
CA2881958A1 (en) 2014-02-20
US20150368263A1 (en) 2015-12-24
PT2882435T (pt) 2021-06-18
US9682997B2 (en) 2017-06-20
EA029363B1 (ru) 2018-03-30
UA120030C2 (uk) 2019-09-25
KR20150042275A (ko) 2015-04-20
JP6400580B2 (ja) 2018-10-03
KR102210848B1 (ko) 2021-02-02
ES2876004T3 (es) 2021-11-11
PL2882435T3 (pl) 2021-10-04
IN2015DN02009A (https=) 2015-08-14
HK1248691A1 (zh) 2018-10-19
JP2018199718A (ja) 2018-12-20
JP2015528823A (ja) 2015-10-01
HUE054955T2 (hu) 2021-10-28
CN107840854A (zh) 2018-03-27
JP6694029B2 (ja) 2020-05-13
ZA201501268B (en) 2016-01-27
CN104736152A (zh) 2015-06-24
EP2882435A1 (en) 2015-06-17
WO2014026254A1 (en) 2014-02-20
EA201590278A1 (ru) 2015-07-30
EP2882435B8 (en) 2024-01-03
HK1206980A1 (en) 2016-01-22
MX380259B (es) 2025-03-12
BR112015002945A2 (pt) 2017-12-05
EP2882435B1 (en) 2021-03-17

Similar Documents

Publication Publication Date Title
CN109942546B (zh) 喹诺酮嘧啶类化合物及其制备方法和应用
AU2014336747B2 (en) Crystal form of (r)-praziquantel and preparation method and application thereof
RU2125571C1 (ru) СОЛЬ 7-([1α,5α,6α]-6-АМИНО-3-АЗАБИЦИКЛО [3.1.0] ГЕКС-3-ИЛ)-6-ФТОР-1-(2,4-ДИФТОРФЕНИЛ)-1,4- ДИГИДРО-4-ОКСО-1,8-НАФТИРИДИН-3-КАРБОНОВОЙ И МЕТАНСУЛЬФОНОВОЙ КИСЛОТ И СПОСОБ ЕЕ ПОЛУЧЕНИЯ
TW200934772A (en) Crystalline(R)-2-(4-cyclopropanesulphonyl-phenyl)-N-pyrazin-2-yl-3-(tetrahydropyran-4-yl)-propionamide
CN104736152B (zh) 包含3‑甲酰基利福霉素sv和3‑甲酰基利福霉素s的3‑(4‑肉桂基‑1‑哌嗪基)氨基衍生物的药物制剂以及它们的制备方法
WO2018000250A1 (zh) 依鲁替尼新晶型及其制备方法
CN102807575B (zh) 3-芳基-5-噻吩基-5H-噻唑并[3,2-a]嘧啶类衍生物及其应用
WO2003000681A1 (en) Antibacterial having quinolinecarboxamide skeleton
US20080234323A1 (en) Amorphous and Three Crystalline Forms of Rimonabant Hydrochloride
TWI705065B (zh) 嗎啉衍生物的鹽及其晶型、其製備方法及藥物組成物、用途
WO2015067130A1 (zh) (s)-奥拉西坦晶型iii及其制备方法和用途
WO2022052925A1 (zh) 一种洛普替尼晶型及其制备方法
CN108440518A (zh) 3-(2-氨基噻唑)-7-取代哌嗪类喹诺酮化合物及其制备方法和应用
CN106928228B (zh) 奥格列汀盐及其晶型、它们的制备方法和药物组合物
CN105085421B (zh) 奥比特嗪‑富马酸盐、水合物、晶型及其制备方法
HK1206980B (en) Pharmaceutical formulations containing 3-(4-cinnamyl-l-piperazinyl) amino derivatives of 3-formylrifamycin sv and 3-formylrifamycin s and a process of their preparation
CN120412812A (zh) 一种clovibactin类似物及其应用
RU2440115C2 (ru) Комбинированные лекарственные препараты, состоящие из солей 2-этил-3-(n, n-диметилкарбамоилокси)-6-метилпиридина с органическими и неорганическими кислотами и янтарной кислоты, обладающие антигипоксической, антиамнестической и противосудорожной активностью
WO2025067474A1 (zh) 一种含吡啶的化合物及其制备方法和用途
CN106699669A (zh) 一种左旋吗啉硝唑晶型及其制备方法和药用组合物的用途
HK1227882B (zh) 一种钠-葡萄糖协同转运蛋白2抑制剂的l-脯氨酸复合物、其一水合物及晶体
HK1247726B (zh) 烟酰胺核苷的结晶形式

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
EXSB Decision made by sipo to initiate substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1206980

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20180301

Address after: Bulgaria Sofia

Co-patentee after: In Ibo Mil Bo Zhidanuofufudulu husband

Patentee after: The single joint-stock company of A Dipamu

Co-patentee after: Base Lille A Senuofu Nino husband

Co-patentee after: Wei Lishikaliliewaa Persian Tuo Luowa-Di Mowa

Co-patentee after: Yi Futi meter Ya Yiwan Nova Si Daifan Nova

Co-patentee after: Luo Sen Crewe is husband Coe Te Qiefu not

Co-patentee after: Di Teqiefu seeks advice from Co., Ltd

Address before: Bulgaria Sofia

Co-patentee before: Bo Daerliubienuofu Fu Dulufu

Patentee before: The single joint-stock company of A Dipamu

Co-patentee before: In Ibo Mil Bo Zhidanuofufudulu husband

Co-patentee before: Base Lille A Senuofu Nino husband

Co-patentee before: Wei Lishikaliliewaa Persian Tuo Luowa-Di Mowa

Co-patentee before: Yi Futi meter Ya Yiwan Nova Si Daifan Nova

Co-patentee before: Luo Sen Crewe is husband Coe Te Qiefu not

Co-patentee before: Di Teqiefu seeks advice from Co., Ltd

TR01 Transfer of patent right
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1206980

Country of ref document: HK